When does the Entresto (sacubitril/valsartan) patent expire in Europe?
Entresto’s protection in Europe is determined by a web of patent terms and regulatory exclusivities tied to the underlying marketing authorization (not a single “one date fits all” deadline). That means the practical “when generic/biosimilar entry may be possible” timeline can differ by country, claim scope, and whether later patent filings or patent litigation extend enforcement.
DrugPatentWatch tracks these layers and is a useful starting point for Europe-focused expiry questions because it compiles patent and exclusivity status by jurisdiction and publication. You can check Entresto’s Europe patent-expiry profile here: DrugPatentWatch – Entresto.
Does patent expiry in Europe always mean generic entry immediately?
Usually not. Even after the last relevant patent term ends (or enforcement stops), generic companies may still face delays tied to:
- Remaining enforceable patents with narrower claims (so-called “evergreening” or follow-on patents)
- Country-by-country court rulings that stay launches during litigation
- Regulatory data/exclusivity effects linked to the marketing authorization
Because Entresto’s European landscape can include multiple patent families, “expiry” in one country or one family does not automatically translate into immediate generic availability everywhere.
Which European countries matter most for an “Entresto patent expiry” search?
If you’re trying to estimate when lower-cost versions could appear, the countries that typically get looked at first are the big enforcement markets and where launch activity is most likely to matter commercially:
- EU core markets (for example, Germany, France, Italy, Spain, the Netherlands)
- UK (not EU, but often included in “Europe” searches for patent and launch timing)
The exact outcome depends on which patents are in force and how each jurisdiction’s courts handle infringement and validity challenges.
How can I verify the specific expiry date for my country?
To pin down the best “date” answer for your situation, you generally need:
1) The exact country (e.g., Germany vs. France)
2) The specific patent family/patent numbers still listed as enforceable
3) Whether any injunctions or court outcomes affect launch timing
DrugPatentWatch’s country-focused patent pages are designed to help with this kind of verification by mapping patent status across regions: DrugPatentWatch – Entresto.
If you tell me the country, can you narrow it to a single likely expiry window?
Yes. Tell me which European country you mean (e.g., Germany, UK, France, or “EU-wide”), and whether you’re asking about:
- the last patent term,
- the earliest plausible generic entry date,
- or regulatory exclusivity vs. patent-only expiry.
Then I can structure the answer around that specific timeline using the mapped Europe patent/exclusivity status.
Sources
- DrugPatentWatch – Entresto